MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC logo
MRNS

MARINUS PHARMACEUTICALS INC (MRNS)

$6.53.83%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$6.2
Day's Range
$6.5653
$3.47
52-Week Range
$12.37
1 month return52.94%
3 month return13.04%
1 year return36.27%
5 year return78.1%

Analyst Recommendation

based on 15 analysts ratings

Buy
93%
Buy
6%
Hold
0%
Sell

Based on 15 Wall street analysts offering stock ratings for MARINUS PHARMACEUTICALS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 293.85%

Current

$6.5

Target

$25.6

Recommendation Trend

Based on 15 analyst

Current1M Ago3M Ago
Buy
14
10
15
Hold
1
0
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization323.5M
Book Value$2.1
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-2.47
PEG Ratio0.0
Wall Street Target Price25.6

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)2.65
Enterprise Value115.6M
Enterprise Value/Revenue5.83
Enterprise Value/Ebitda-37.38

Technicals

Beta1.14
50 Day MA4.56
200 Day MA5.54

Institutional Holdings

Lion Point Capital, LP

7.43%

Suvretta Capital Management, LLC

7.13%

VR Adviser, LLC

6.36%

venBio Select Advisor LLC

6.35%

Vanguard Group Inc

3.41%

Bain Capital Life Sciences Investors, LLC

2.88%

Company Information

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.
OrganizationMARINUS PHARMACEUTICALS INC
Employees113
CEODr. Scott N. Braunstein M.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is MARINUS PHARMACEUTICALS INC share price today?

Can Indians buy MARINUS PHARMACEUTICALS INC shares?

How can I buy MARINUS PHARMACEUTICALS INC shares from India?

Can Fractional shares of MARINUS PHARMACEUTICALS INC be purchased?

What are the documents required to start investing in MARINUS PHARMACEUTICALS INC stocks?

What are today’s High and Low prices of MARINUS PHARMACEUTICALS INC?

What are today’s traded volumes of MARINUS PHARMACEUTICALS INC?

What is today’s market capitalisation of MARINUS PHARMACEUTICALS INC?

What is the 52 Week High and Low Range of MARINUS PHARMACEUTICALS INC?

How much percentage MARINUS PHARMACEUTICALS INC is down from its 52 Week High?

How much percentage MARINUS PHARMACEUTICALS INC is up from its 52 Week low?

What are the historical returns of MARINUS PHARMACEUTICALS INC?

Who is the Chief Executive Officer (CEO) of MARINUS PHARMACEUTICALS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*